---
document_datetime: 2025-12-19 09:24:56
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ruconest-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ruconest-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3608917
conversion_datetime: 2025-12-22 11:07:06.70503
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ruconest

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 27/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000263304                     | PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from Ruconest EU registry listed as a category 3 study in the RMP. This is a non-imposed non- interventional PASS (phase IV) of C1 inhibitor Treatment Registry to assess the Safety and Immunological Profile of Ruconest in the treatment of HAE Attacks. Version 21.0 of the RMP has also been submitted.   |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000267751 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/05/2025 | N/A |             |
| PSUR / EMA/PSUR/0000248470            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Maintenance |
| PSUR / EMA/PSUR/0000288246            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Maintenance |